Laboratoires Thea

Address: Zone Industrielle Du Brezet, 12 Rue Louis Bleriot

Sponsor Overview

assignment

Specializations

Ophthalmic inflammation and allergic eye disease

Research activity includes vernal keratoconjunctivitis, with interest in controlling keratitis, ocular surface inflammation, and symptoms affecting the cornea and surrounding tissues.

Vernal keratoconjunctivitis
Corneal inflammation
Ocular allergy

Clinical work in this area reflects a focus on chronic immune-mediated eye disorders that can impair comfort, vision, and ocular surface integrity.

Inherited retinal dystrophies

The sponsor supports studies in retinitis pigmentosa, with attention to inherited disorders that progressively affect retinal function and visual performance.

Retinitis pigmentosa
Inherited retinal disease
Visual impairment

This area includes genetically defined forms of retinal degeneration linked to US2H2A-related disease mechanisms.

Genetic eye disease and gene-targeted therapy

Trials also address Leber congenital amaurosis, with interest in rare monogenic retinal disorders associated with specific CEP290 variants.

Leber congenital amaurosis
CEP290-related disease
Inherited blindness

These studies are centered on severe early-onset retinal conditions where preserving or improving photoreceptor and retinal signaling function is central.

Ocular therapeutics and topical treatment evaluation

Laboratoires Thea’s portfolio includes comparative research in ophthalmic anti-inflammatory treatment, with attention to effectiveness, safety, and tolerability in eye disease.

Topical ophthalmic therapy
Safety and tolerability
Corneal and retinal outcomes

The research spans both surface eye disorders and degenerative retinal conditions, showing interest in distinct therapeutic needs across ophthalmology.

Sponsored Trials

Trial Name	Country	Status
Efficacy and safety assessment of T1695 ophthalmic suspension, versus Ciclosporin ophthalmic emulsion, in participants with moderate to severe Vernal Keratoconjunctivitis (VKC)	Bulgaria France Greece Italy Spain	Not Yet Recruiting
Evaluation of Sepofarsen Efficacy, Safety, and Tolerability in Leber Congenital Amaurosis Patients with CEP290 c.2991+1655A>G Mutation: A Randomized, Placebo-Controlled Study	Belgium France Germany Spain The Netherlands	Recruiting
Evaluation of Ultevursen Efficacy, Safety, and Tolerability in Retinitis Pigmentosa Patients with USH2A Exon 13 Mutations: A Double-Masked, Randomized, Sham-Controlled Trial	Belgium Denmark France Germany Italy The Netherlands	Not Recruiting
Evaluation of Ultevursen Efficacy, Safety, and Tolerability in Retinitis Pigmentosa Patients with USH2A Exon 13 Mutations: A Two-Year Randomized, Sham-Controlled Study	France Germany Italy The Netherlands	Not Yet Recruiting
Safety and efficacy of sodium phenylbutyrate eye drops for paediatric myopia progression	Ireland	Recruiting